Altimmune (ALT) Stock Analysis & AI Equity Report

Biotechnology USD Explore free reports

Altimmune (ALT) overview

Altimmune (ALT) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 0.0m and operating profit of USD -94.5m; the year-end share price was 3.61 USD and market capitalisation was USD 400m. Altimmune is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Altimmune's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.

Key metrics & valuation multiples

Book valueUSD 225mFY 2025
Share price3.61 USDFY 2025 year end
RevenueUSD 0.0mFY 2025
Operating profitUSD -94.5mFY 2025
Net earningsUSD -88.1mFY 2025
Market capitalisationUSD 400mFY 2025 year end

About Altimmune

Altimmune is a clinical-stage biopharmaceutical company developing pemvidutide, an investigational balanced glucagon/GLP-1 dual-receptor agonist. The candidate is being studied for metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder and alcohol-associated liver disease. Its pipeline includes a global Phase 3 MASH trial, results from a completed Phase 2 alcohol-use-disorder study, and an ongoing Phase 2 study in alcohol-associated liver disease.

Generate the Altimmune report

Altimmune is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.

Generate fresh report — €50.00 Delivered by email, usually within an hour

Sources & methodology

Financial figures are sourced from Valuatum's financial model for Altimmune and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.

Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.

Analyst reports on Altimmune

Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.